R. E. Mansel, L. Fallowfield, M. Kissin, A. Goyal, R. G. Newcombe, J. M. Dixon, C. Yiangou, K. Horgan, N. Bundred, I. Monypenny, D. England, M. Sibbering, T. I. Abdullah, L. Barr, U. Chetty, D. H. Sinnett, A. Fleissig, D. Clarke and P. J. Ell, “Randomized Multicenter Trial of Sentinel Node Biopsy versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial,” Journal of the National Cancer Institute, Vol. 98, No. 9, 2006, pp. 599-609. http://dx.doi.org/10.1093/jnci/djj158

has been cited by the following article:

• TITLE: No Axillary Lymph Node Dissection in Breast Cancer Patients with Sentinel Lymph Node Micrometastasis

  AUTHORS: Marco Gipponi, Piero Fregatti, Federica Murelli, Paolo Meszaros, Francesca Depaoli, Cecilia Margarino, Paola Baccini, Marina Gualco, Daniele Friedman

  KEYWORDS: Sentinel Lymph Node; Axillary Lymph Node Dissection; Breast Cancer

  JOURNAL NAME: Advances in Breast Cancer Research, Vol.3 No.1, January 17, 2014

  ABSTRACT: Follow-up data of a series of 75 breast cancer patients with sentinel node (SN) micrometastases only (between 0.2 and 2 mm) and favorable histopathological features of the primary tumor (well-differentiated, T1 tumors without lymphovascular invasion) who refused completion axillary lymph node dissection (ALND) or who were unsuitable for surgery were assessed in order to detect the rate of axillary recurrence after an adjuvant chemoand/or hormonal adjuvant treatment was given. The great majority of patients (81.3%) did not undergo ALND due to the existence of favorable histopathologic factors while the rest were equally distributed among over 75-year-old women (10.6%) and patients at a high surgical risk due to comorbid conditions (9.3%). Sixty-six patients (88%) underwent conservative treatment (lumpectomy followed by adjuvant breast radiotherapy) while the remaining nine patients (12%) had total mastectomy; 72 out of 75 patients (96%) received some forms of adjuvant chemoand/or hormone-therapy. After a median follow-up of 38 months (range 12 - 84 months), nine out of 75 patients (12%) had a disease relapse, only one of them (1.3%) being affected by an axillary recurrence in the untreated axilla three years after primary surgery. On these grounds, completion ALND could be safely omitted in patients with SN micrometastasis and favorable histopathological characteristics of the primary neoplasm due to the very low rate of axillary recurrence with no detrimental effect on survival.